Sovran Advisors LLC Has $852,000 Position in HCA Healthcare, Inc. $HCA

Sovran Advisors LLC lessened its stake in shares of HCA Healthcare, Inc. (NYSE:HCA) by 29.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,256 shares of the company’s stock after selling 962 shares during the period. Sovran Advisors LLC’s holdings in HCA Healthcare were worth $852,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of HCA. Cheviot Value Management LLC acquired a new position in HCA Healthcare during the first quarter worth $26,000. Saudi Central Bank acquired a new position in HCA Healthcare during the first quarter worth $26,000. WPG Advisers LLC acquired a new position in HCA Healthcare during the first quarter worth $27,000. Atwood & Palmer Inc. acquired a new position in HCA Healthcare during the first quarter worth $28,000. Finally, Bartlett & CO. Wealth Management LLC grew its stake in shares of HCA Healthcare by 888.9% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 89 shares of the company’s stock worth $31,000 after acquiring an additional 80 shares in the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

NYSE HCA opened at $400.95 on Friday. The firm has a market cap of $93.82 billion, a P/E ratio of 16.85, a price-to-earnings-growth ratio of 1.26 and a beta of 1.41. The company has a quick ratio of 0.86, a current ratio of 0.98 and a debt-to-equity ratio of 69.07. The company’s 50 day moving average is $384.69 and its 200-day moving average is $365.16. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $420.98.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings results on Friday, July 25th. The company reported $6.84 EPS for the quarter, beating analysts’ consensus estimates of $6.20 by $0.64. The company had revenue of $18.61 billion for the quarter, compared to analysts’ expectations of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. HCA Healthcare’s revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the company posted $5.50 EPS. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Sell-side analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Tuesday, September 16th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Tuesday, September 16th. HCA Healthcare’s dividend payout ratio is presently 12.11%.

Insider Activity at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,836 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the transaction, the executive vice president directly owned 31,503 shares in the company, valued at approximately $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

HCA has been the subject of several recent analyst reports. Wells Fargo & Company reduced their target price on shares of HCA Healthcare from $385.00 to $375.00 and set an “equal weight” rating for the company in a research note on Thursday, August 14th. Morgan Stanley reduced their target price on shares of HCA Healthcare from $410.00 to $400.00 and set an “equal weight” rating for the company in a research note on Monday, July 28th. Robert W. Baird upped their target price on shares of HCA Healthcare from $380.00 to $423.00 and gave the stock a “neutral” rating in a research note on Thursday, August 14th. Stephens upgraded shares of HCA Healthcare to a “strong-buy” rating in a research note on Monday, June 2nd. Finally, Truist Financial increased their price target on shares of HCA Healthcare from $390.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $407.75.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.